CSL to manufacture UQ and Oxford COVID-19 vaccines for Australia

CSL to manufacture UQ and Oxford COVID-19 vaccines for Australia

Biotechnology giant CSL (ASX: CSL) will manufacture more than 80 million doses of COVID-19 vaccines for supply in Australia, slated for release in 2021.

The manufacture and supply agreements are contingent on the success of clinical trials at both the University of Queensland and Oxford University where the vaccines are being developed.

Once trials are complete, the deals will see 52 million doses of UQ's vaccine made by CSL for Australia, plus 30 million doses of the Oxford vaccine.

First doses of the UQ vaccines are scheduled for release in mid-2021, while Oxford's would be ready in early 2021.

UQ is currently undertaking Phase 1 clinical studies on its vaccine to assess how safe it is in healthy human volunteers.

"The social and economic impact of the COVID-19 pandemic has brought a high level of urgency to the task of developing a vaccine against the SARS-CoV-2 virus, and to manufacture a successful vaccine at high quality and in sufficient quantities," says CSL CEO and managing director Paul Perreault.

"CSL has been working at pace to respond to the pandemic and has invested significant resources in the rapid development and large-scale manufacture of UQ-CSL V451, along with a number of other therapeutic programs.

"Together with partners including the University of Queensland and Coalition for Epidemic Preparedness (CEPI), our development and manufacturing teams have been working extremely hard to advance this program to ensure the availability of a safe and effective vaccine should clinical studies prove successful."

Perreault says results from the pre-clinical and early clinical studies for UQ's vaccine are promising, but he notes it is impossible to predict the level of success the university will have in late stage trials.

"CSL's focus is to produce a safe and effective vaccine," says Perreault.

"It is important that on completion of clinical trials, the public has confidence in UQ-CSL V451, which makes use of the well-established recombinant protein technology platform, and Seqirus' proprietary adjuvant MF59, which has an extensively safety track record in humans."

Shares in CSL are up 0.30 per cent to $279.89 per share at 10:57am AEST.

Updated at 11.19am AEST on 7 September 2020.

Enjoyed this article?

Don't miss out on the knowledge and insights to be gained from our daily news and features.

Subscribe today to unlock unlimited access to in-depth business coverage, expert analysis, and exclusive content across all devices.

Support independent journalism and stay informed with stories that matter to you.

Subscribe now and get 50% off your first year!

Four time-saving tips for automating your investment portfolio
Partner Content
In today's fast-paced investment landscape, time is a valuable commodity. Fortunately, w...
Etoro
Advertisement

Related Stories

Ocean Guardian administrator in talks with "several parties" to secure its future

Ocean Guardian administrator in talks with "several parties" to secure its future

After two withdrawn initial public offering (IPO) attempts in 2018 ...

Westpac breached Banking Code of Practice in NT branch closure, putting vulnerable customers at risk

Westpac breached Banking Code of Practice in NT branch closure, putting vulnerable customers at risk

The independent body tasked with keeping bank behaviour in check ha...

Cyber security consultancy CSO Group to merge with AI enabler xAmplify

Cyber security consultancy CSO Group to merge with AI enabler xAmplify

Sydney-based cyber security consultancy CSO Group is set to join fo...

Julian Assange will be freed after striking plea deal with US authorities

Julian Assange will be freed after striking plea deal with US authorities

Julian Assange has reached a deal with the United States Department...